CoQ10vsPEA (Palmitoylethanolamide)

CoQ10 (ubiquinone/ubiquinol) shuttles electrons between Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase) and Complex III (cytochrome bc1 complex) of the mitochondrial electron transport chain. This is the fundamental process of oxidative phosphorylation—electrons flow through the chain to Complex IV, driving proton pumping and ATP synthesis via Complex V (ATP synthase). Without adequate CoQ10, the chain bottlenecks at the CoQ pool and energy production drops, particularly in high-metabolic tissues like neurons. As a lipid-soluble antioxidant, CoQ10 (in its reduced ubiquinol form) protects mitochondrial membranes from lipid peroxidation by terminating free radical chain reactions. It also regenerates vitamin E (tocopherol) from its radical form, amplifying antioxidant capacity. Brain CoQ10 levels decline with age.

PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.